Emmaus gets marketing authorization for SCD treatment Endari in Oman

Emmaus Life Sciences announced that it has received marketing authorization from the Oman Ministry of Health for the commercial distribution and sale of Endari or L-glutamine oral powder in the country to treat sickle cell disease in patients five years of age and older.There are around 3,000 patients with sickle cell disorders in Oman1. The birth prevalence of infants with hemoglobin disorders was 3.5-4.7 per 1,000. Around 6% of Omanis are carriers of the gene for sickle cell anaemia .”We are delighted to receive marketing authorization for Endari in Oman, where sickle cell disease is a significant public health issue that affects thousands of patients and their families,” said Dr. Yutaka Niihara, M.D., M.P.H., Chairman and Chief Executive Officer of Emmaus. “This approval marks another milestone in our mission to improve the lives of people with sickle cell disease around the world.”